FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127160975> ?p ?o ?g. }

• W2127160975 endingPage "1057" @default.
• W2127160975 startingPage "1048" @default.
• W2127160975 abstract "This study evaluated effects of protease-activated receptor-1 antagonist vorapaxar (Merck, Whitehouse Station, New Jersey) versus placebo among the TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) study patients with non–ST-segment elevation acute coronary syndromes undergoing coronary artery bypass grafting (CABG). Platelet activation may play a key role in graft occlusion, and antiplatelet therapies may reduce ischemic events, but perioperative bleeding risk remains a major concern. Although the TRACER study did not meet the primary quintuple composite outcome in the overall population with increased bleeding, an efficacy signal with vorapaxar was noted on major ischemic outcomes, and preliminary data suggest an acceptable surgical bleeding profile. We aimed to assess efficacy and safety of vorapaxar among CABG patients. Associations between treatment and ischemic and bleeding outcomes were assessed using time-to-event analysis. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using the Cox hazards model. Event rates were estimated using the Kaplan-Meier method. Among 12,944 patients, 1,312 (10.1%) underwent CABG during index hospitalization, with 78% on the study drug at the time of surgery. Compared with placebo CABG patients, vorapaxar-treated patients had a 45% lower rate of the primary endpoint (i.e., a composite of death, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization during index hospitalization) (HR: 0.55; 95% CI: 0.36 to 0.83; p = 0.005), with a significant interaction (p = 0.012). The CABG-related Thrombolysis In Myocardial Infarction major bleeding was numerically higher with vorapaxar, but not significantly different between vorapaxar and placebo (9.7% vs. 7.3%; HR: 1.36; 95% CI: 0.92 to 2.02; p = 0.12), with no excess in fatal bleeding (0% vs. 0.3%) or need for reoperation (4.7% vs. 4.6%). In non–ST-segment elevation acute coronary syndrome patients undergoing CABG, vorapaxar was associated with a significant reduction in ischemic events and no significant increase in major CABG-related bleeding. These data show promise for protease-activated receptor 1 antagonism in patients undergoing CABG and warrant confirmatory evidence in randomized trials. (Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Acute Coronary Syndrome [TRA·CER] [Study P04736AM3]; NCT00527943)" @default.
• W2127160975 created "2016-06-24" @default.
• W2127160975 creator A5005158159 @default.
• W2127160975 creator A5005442097 @default.
• W2127160975 creator A5010466306 @default.
• W2127160975 creator A5021191954 @default.
• W2127160975 creator A5024015419 @default.
• W2127160975 creator A5032690649 @default.
• W2127160975 creator A5033070568 @default.
• W2127160975 creator A5033136642 @default.
• W2127160975 creator A5037527199 @default.
• W2127160975 creator A5038384001 @default.
• W2127160975 creator A5039432822 @default.
• W2127160975 creator A5039450208 @default.
• W2127160975 creator A5048065442 @default.
• W2127160975 creator A5053784003 @default.
• W2127160975 creator A5057728240 @default.
• W2127160975 creator A5059011787 @default.
• W2127160975 creator A5060370891 @default.
• W2127160975 creator A5062843291 @default.
• W2127160975 creator A5063591215 @default.
• W2127160975 creator A5075973255 @default.
• W2127160975 creator A5077862111 @default.
• W2127160975 creator A5085975703 @default.
• W2127160975 creator A5087154648 @default.
• W2127160975 creator A5090147492 @default.
• W2127160975 date "2014-03-01" @default.
• W2127160975 modified "2023-09-27" @default.
• W2127160975 title "Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery" @default.
• W2127160975 cites W111766519 @default.
• W2127160975 cites W1553345686 @default.
• W2127160975 cites W1597535871 @default.
• W2127160975 cites W177712551 @default.
• W2127160975 cites W1951459738 @default.
• W2127160975 cites W1990799972 @default.
• W2127160975 cites W1997343401 @default.
• W2127160975 cites W2008831395 @default.
• W2127160975 cites W2011101439 @default.
• W2127160975 cites W2013172045 @default.
• W2127160975 cites W2019056275 @default.
• W2127160975 cites W2023325651 @default.
• W2127160975 cites W2024141041 @default.
• W2127160975 cites W2055698835 @default.
• W2127160975 cites W2061837685 @default.
• W2127160975 cites W2062841731 @default.
• W2127160975 cites W2079964926 @default.
• W2127160975 cites W2099717909 @default.
• W2127160975 cites W2123673539 @default.
• W2127160975 cites W2126340461 @default.
• W2127160975 cites W2134322421 @default.
• W2127160975 cites W2135780868 @default.
• W2127160975 cites W2140991303 @default.
• W2127160975 cites W2142021807 @default.
• W2127160975 cites W2144808837 @default.
• W2127160975 cites W2145920380 @default.
• W2127160975 cites W2148737731 @default.
• W2127160975 cites W2152304396 @default.
• W2127160975 cites W2153375213 @default.
• W2127160975 cites W2156255513 @default.
• W2127160975 cites W2156266070 @default.
• W2127160975 cites W2616651817 @default.
• W2127160975 cites W303795847 @default.
• W2127160975 cites W4255225463 @default.
• W2127160975 cites W79691165 @default.
• W2127160975 doi "https://doi.org/10.1016/j.jacc.2013.10.048" @default.
• W2127160975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24211500" @default.
• W2127160975 hasPublicationYear "2014" @default.
• W2127160975 type Work @default.
• W2127160975 sameAs 2127160975 @default.
• W2127160975 citedByCount "41" @default.
• W2127160975 countsByYear W21271609752014 @default.
• W2127160975 countsByYear W21271609752015 @default.
• W2127160975 countsByYear W21271609752016 @default.
• W2127160975 countsByYear W21271609752017 @default.
• W2127160975 countsByYear W21271609752018 @default.
• W2127160975 countsByYear W21271609752019 @default.
• W2127160975 countsByYear W21271609752020 @default.
• W2127160975 countsByYear W21271609752021 @default.
• W2127160975 countsByYear W21271609752023 @default.
• W2127160975 crossrefType "journal-article" @default.
• W2127160975 hasAuthorship W2127160975A5005158159 @default.
• W2127160975 hasAuthorship W2127160975A5005442097 @default.
• W2127160975 hasAuthorship W2127160975A5010466306 @default.
• W2127160975 hasAuthorship W2127160975A5021191954 @default.
• W2127160975 hasAuthorship W2127160975A5024015419 @default.
• W2127160975 hasAuthorship W2127160975A5032690649 @default.
• W2127160975 hasAuthorship W2127160975A5033070568 @default.
• W2127160975 hasAuthorship W2127160975A5033136642 @default.
• W2127160975 hasAuthorship W2127160975A5037527199 @default.
• W2127160975 hasAuthorship W2127160975A5038384001 @default.
• W2127160975 hasAuthorship W2127160975A5039432822 @default.
• W2127160975 hasAuthorship W2127160975A5039450208 @default.
• W2127160975 hasAuthorship W2127160975A5048065442 @default.
• W2127160975 hasAuthorship W2127160975A5053784003 @default.
• W2127160975 hasAuthorship W2127160975A5057728240 @default.
• W2127160975 hasAuthorship W2127160975A5059011787 @default.
• W2127160975 hasAuthorship W2127160975A5060370891 @default.
• W2127160975 hasAuthorship W2127160975A5062843291 @default.

• next